Tweets
Abs#518 @RheumNow #ACR23
Deodhar: TOFA in AS, by b/l CRP levels
30% nml CRP (<5 mg/L) v 70% Elevated
At wk 12, TOFA >> PBO regardless of b/l CRP
Difference in response: greater in pts w elevated CRP
Safety rates: elev. CRP c/w PBO, but nml CRP had trend of high AEs for tofa v PBO https://t.co/b9NRNkU8ub
Eric Dein ( View Tweet )
2 years 3 months ago
Are Long-term NSAIDs safe in AS?
Ab#0528 #ACR23 @RheumNow
19,775 AS pts vs 59,325 controls.
Incidence of 16.9, 13.8 per 1,000 person-yrs, respectively
Long-term use of NSAIDs increased risk of CVD in non-AS control (aHR 1.64), but did NOT in AS pts (aHR 1.06)
Eric Dein ( View Tweet )
2 years 3 months ago
Differences in #glucocorticoid dosing. In #lupus #nephritis less steroids are the same as high dose steroids. Placebo arms of pooled data from #LN #RCTs. Less is equal! #ACRbest #ACR2023 @RheumNow @ACRheum abst0781 High dose steroids tended to have lower MMF doses https://t.co/XwTlsy4xKE
Janet Pope ( View Tweet )
2 years 3 months ago
Plasma MMPs and RA-ILD. Strong association MMPs 7 & 9 with prevalent RA-ILD. Abstr#0770 #ACR23 @RheumNow https://t.co/5qWeK3lAly https://t.co/SyZY2OhcbH
Richard Conway ( View Tweet )
2 years 3 months ago
2 yrs extension of DRESS-PS study
100+ pts w/ PsA and AxSPA
-70% LDA state in both Ctrl & Intervention gps
-strong recovery after relapse
No difference efficacy protocolized & routine care tapering but inferior TNFi use (52 vs. 77%) in Intervention gp
@RheumNow #ACR23 ABST0775 https://t.co/V2DqCjT0w3
Aurelie Najm ( View Tweet )
2 years 3 months ago
#ACR23
IV secukinumab vs placebo at 52 Weeks
@RheumNow https://t.co/4zQa37tN4l
Dellal ( View Tweet )
2 years 3 months ago
Abs#0608 #ACR23 @RheumNow
Cenerimod: sphigosine 1-phos (S1P) 1 receptor modulator for SLE
P2 CARE Study
51% of pts had high IFN1 sign., ass w/ high dsDNA
Cenerimod 4 mg: decreased dsDNA and IFN-a protein at 6 mo vs b/l
In high IFN pts, 4 mg Cen: decrease SLEDAI, SRI-4
Eric Dein ( View Tweet )
2 years 3 months ago
Abs#595 #ACR23 @RheumNow
R Furie on 4 yr TULIP-LTE pts with b/l renal involvement
33% on anifrolumab continued to wk 208 vs PBO 6%
Renal improvement at w208 in 9/10 pts, vs no avail PBO data
Conclusion: more Anifrolumab pts remained in study & reached SLEDAI-2K renal improvement
Eric Dein ( View Tweet )
2 years 3 months ago
Cowley et al @sharoncowley01 Subclinical GCA in 17.5% with new PMR. Males with higher ESR more likely to have subclinical GCA. Subclinical GCA more axillary artery. Abstr#0747 #ACR23 #ACRbest @RheumNow https://t.co/CghmX1TKpf https://t.co/MJawtslLud
Richard Conway ( View Tweet )
2 years 3 months ago
Phase 3 Study of IV Secukinumab for treatment of PsA - efficacious and safety profile similar to Subq version
~60% ACR 50 response maintained at week 52
2nd responses of MDA, PASI90, enthesitis, dactylitis resolution met
@RheumNow #ACR23 Abs#0776 https://t.co/jikWd4fnGm
Robert B Chao, MD ( View Tweet )
2 years 3 months ago
Entrevista de @RheumNow a las doctoras Griselda Serna Peña y Diana Flores Gutierrez sobre su trabajo de Screening y salud secual en pacientes con enfermedades reumáticas
#ACR23 @SernaDra @ColMexReuma https://t.co/SyuFVXM9Sf
ReumaJoven ( View Tweet )
2 years 3 months ago
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty
Dr. John Cush @RheumNow ( View Tweet )
2 years 3 months ago
